[Immunogenicity of biosimilars]

Area of Science:

• Biopharmaceuticals
• Drug Development
• Regulatory Science

Background:

• Complex recombinant protein drugs, including monoclonal antibodies and fusion proteins, are increasingly available as biosimilars.
• Regulatory agencies like the EMA mandate extensive comparability exercises to ensure biosimilar quality, safety, and efficacy match reference products.
• Immunogenicity is a critical factor requiring rigorous assessment for both biosimilar and reference products.

Purpose of the Study:

• To examine the assessment process and decision-making by authorities regarding the biosimilarity of complex recombinant protein drugs.
• To analyze specific case studies involving etanercept and infliximab biosimilars.
• To highlight potential discrepancies in the evaluation of biosimilarity and the need for ongoing surveillance.

Main Methods:

• Review of regulatory guidelines (e.g., EMA) for biosimilar comparability.
• Analysis of assessment data for etanercept and infliximab biosimilars.
• Evaluation of authorities' opinions on biosimilarity and remaining uncertainties.

Main Results:

• Demonstrated the process by which regulatory authorities assess biosimilarity data for complex biologics.
• Highlighted that consensus on biosimilarity is not always reached before marketing authorization.
• Identified specific challenges in evaluating immunogenicity and overall biosimilarity.

Conclusions:

• Extensive comparability studies are essential for biosimilar approval.
• Ongoing monitoring of biosimilars post-marketing authorization is vital, as emphasized by the Dutch Medicines Evaluation Board.
• Ensuring biosimilarity, particularly regarding immunogenicity, requires continuous vigilance to maintain patient safety and therapeutic equivalence.